Buradasınız

Anasayfa » Content

Aterosklerotik Koroner Arter Hastalığı Tespit Edilenlerde Plazma Homosistein Düzeyi

Plasma Homocysteine Levels in Patients with Atherosclerotic Coronary Artery Disease

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2001

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Inherited disorders of amino acid metobolism or homocysteine metobolism have been implicated in the pathogenesis of vascular disease. The authors investigated the clinical significance of homocysteine level determination in diagnosis of coronary artery disease (CAD). The study patients (n—80), based on angiographic results, were categorized as a normal coronary group (n—30) and a CAD group (n —50). Patients with coronary artey disease had a higher homocysteine level than control subjects (19.47 +7.13 vs 9.21+5.14 nmol/ml, p<0.001). High density lipoprotein (HDL) cholesterol levels were lower (31 +12 vs 47+16 nmol/ml, p<0.05) and triglycerides levels were higher (198+56 vs 142+24 mg/dl, p<0.05) in patients with coronary artey disease. However plasma total cholesterol and low density lipoprotein (LDL) cholesterol levels were not significantly different between patients with coronary disease and cont rol subjects. In addition the percentage of hypertension (HT), diabetes mellitus (DM), and cigarette smokers between CAD and control groups differed significantly (for all, p<0.05). Our data suggest that hyperhomocysteinemia is highly prevalent in patients with risk factor for atherosclerosis. Homocysteine level should be measured routinely in patients with risk factors for atherosclerosis and treated.
Bookmark/Search this post with
Abstract (Original Language): 
Amino asi t metabolizması veya homosistein metabolizmasına ait kalıtsal bozukluklar v asküler hastalıkların patogenezinde söz edilmektedir. Biz koroner arter hastalığının (KAH) teşhisinde homosistein seviyesinin saptanmasının klinik önemini araştırdık. Çalışma hastaları (n—80) anjiyografik sonuçlara dayanarak normal koroneri olan grup (n—30) ve koroner arter hastalığı olan grup (n—50) olarak katogorize edildi. Koroner arter hastalığı olan hastalar normal kontrol grubundan daha yüksek homosistein düzeylerine sahipti(19.47 +7.13'e karşın 9.21+5.14 nmol/ml, p<0.001). Koroner arter hastalarında yüksek dansiteli lipoprotein (HDL) düzeyleri daha düşük (31+12'e karşın 47+16 nmol/ml, p<0.05), ve trigliserit düzeyleri daha yüksek idi (198 +56'e karşın 142+24 mg/dl, p<0.05). Fakat KAH grubu ile kontrol grubu arasında plazma total kolesterol ve düşük dan siteli lipoprotein düzeyleri açısından önemli bir fark yoktu. Ayrıca KAH grubu ile kontrol grubunda hipertansiyon (HT), diabetes mellitus (DM) ve sigara içiciliğinin yüzdesi açısından önemli bir fark vardı (Hepsi için, p<0.05). Bizim verilerimiz hiperhomosisteineminin ateroskleroz için risk faktörlerine sahip hastalarda yüksek prevalansa sahip olduğunu göstermektedir. Ateroskleroz için risk faktörleri incelemesinde homosistein seviyesine de rutin bakılmalı ve tedavi edilmelidir.
FULL TEXT (PDF): 
PDF icon arastirmax-aterosklerotik-koroner-arter-hastaligi-tespit-edilenlerde-plazma-homosistein-duzeyi.pdf
  • 4
189-191
  • Turkish

REFERENCES

References: 

1. Genest JJ, McNamara JR, Salem DN, Wılson PWF, Schaefer EJ, Malınow MR. Plasma homocystein levels in men with premature coronary artery disease. J Am Cardiol 1990;16:1114-9.
2. Mayer EL, Jacobsen DW, Robınson K Homocysteine and coronary atherosclerosis. J AM Cardiol 1996;27:517 -27.
3. Tsai WC, Li YH, Tsai LM, Chao TH, Lin LJ, Chen TY, Chen JH. C orrelation of homocysteine levels with the extent of coronary atherosclerosis in patients with low cardiovascular risk profiles. Am J Cardiol 2000 ;85:49 -52.
4. Clarke R, Daly L, Robinson K, Naughten E, Chalane S, Fowler B, Graham I. Hyperhomocysteinemia : an independent risk faktor for vascular disease. N Engl J
Med 1991;324:1149-55
5. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland PM, Kvale G. Total plasma homocysteine and cardiovascular risk profile. JAMA
1995;274:1526-33.
6. Chai AU, Abrams J. Homocysteine: a new cardiac risk factor" Clin Cardiol 2001;24:80-4
7.
Gürbü
z M, Aydınlar A, İlçöl Y, Gemici K, Ercan İ, Baran İ, Güllülü S, Cordan J. Homosisteinin Aterosklerotik Koroner Arter Hastalığındaki Rolü, Lezyon ağırlığı, B12 Vitamini ve Folik Asit İle İlişkisi. Türk Kardiyol Dern Arş 2001; 29:695 -702
8.
Suc
u M, Karadede AA, Toprak N. Homosistein ve Kardiyovasküler Hastalıkları Türk Kardiyol Dern Arş 2001; 29:181 -190
9. Blum A, Lupovitch S, Khazim K, Peleg A, Gumanovsky M, Yeganeh S, Jawabreh S. Homocysteine levels in patients with risk factors for atherosclerosis. Clin
Cardiol 2001;24:463-66.
10. Malinow MR,
Kan
g SS, Taylor LM. Prevalance of hyperhomocyst(e)inemia in patients with peripheral arterial arterial occlusive arterial disease.Circulation
1989;79:1180-8.
11. Brattstrom LE, Hardebo JE, Hultberg BL. Moderate homocysteinemia: a possible risk factor for atherosclerotic cerebrovascular disease.Stroke 1984;15:1012 -6.
12. Wileken DEL, Reddy SG, Gupta VJ. Homocysteinemia, ischemic heart disease, and carrier state for homocystinuria. Metabolism 1983;32:363 -70.
13. Israelson B, Brattstrom LE, Hultberg BL. Homocystein and myocardial
infarction. Atherosclerosis 1988;72:227 -33.
14. Ali A, Mehra MR, Lavie CJ, Malik FS, Murgo JP, Lohmann TP, Li S, Lin HC, Milani RV. Modulatory impact of cardiac rehabilitation on hyperhomocysteinemia in patients with coronary artery disease and normal lipid levels. Am J Cardiol
1998;82:1543-44.

Thank you for copying data from http://www.arastirmax.com